Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-1121B with or without dacarbazine in metastatic malignant melanoma
2007-006713-16Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in melanoma comparing IMC-1121B monotherapy with IMC-1121B + dacarbazine (2 arms). Primary endpoint: Progression-free survival. Started Jul 2008; status: terminated.
02
Drugs
ramucirumabdacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2007-006713-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006713-16.